<!DOCTYPE html>
<html lang="en">
<head>
 <meta charset="UTF-8">
 <meta name="viewport" content="width=device-width, initial-scale=1.0">
 <title>Lesson 1: The Legacy of the Women's Health Initiative (WHI) | AccrediPro Academy</title>
 <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&display=swap" rel="stylesheet">
 <style>
/* ===========================================
 ACCREDIPRO GOLD STANDARD - UNIFIED LESSON CSS v5.0
 School-Quality â€¢ ASI Certified â€¢ Premium UX
 =========================================== */

/* Reset & Base */
* {
 box-sizing: border-box;
 margin: 0;
 padding: 0;
}

body {
 font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
 line-height: 1.8;
 color: #1f2937;
 background: #ffffff;
 font-size: 17px;
}

/* MAIN WRAPPER */
.lesson-wrapper {
 max-width: 1200px;
 margin: 0 auto;
 padding: 40px 20px;
}

/* HEADER CARD - Premium Gradient */
.module-header-card {
 background: linear-gradient(135deg, #722F37 0%, #722F37 50%, #5a252b 100%);
 padding: 48px 40px;
 margin-bottom: 40px;
 border-radius: 24px;
 box-shadow: 0 20px 60px -15px rgba(114, 47, 55, 0.4);
 border: none;
 text-align: center;
 position: relative;
 overflow: hidden;
}

.module-header-card::before {
 content: '';
 position: absolute;
 top: -50%;
 left: -50%;
 width: 200%;
 height: 200%;
 background: radial-gradient(circle, rgba(255, 255, 255, 0.05) 0%, transparent 70%);
 pointer-events: none;
}

.module-label {
 font-size: 12px;
 text-transform: uppercase;
 letter-spacing: 3px;
 color: rgba(255, 255, 255, 0.8);
 margin-bottom: 12px;
 font-weight: 600;
 display: block;
}

.lesson-title {
 font-size: 38px;
 color: #ffffff;
 font-weight: 800;
 margin: 0 0 20px 0;
 line-height: 1.15;
 text-shadow: 0 2px 4px rgba(0, 0, 0, 0.1);
}

/* META BADGES */
.lesson-meta {
 display: flex;
 justify-content: center;
 gap: 12px;
 flex-wrap: wrap;
}

.meta-badge {
 background: rgba(255, 255, 255, 0.15);
 color: white;
 padding: 8px 18px;
 border-radius: 24px;
 font-size: 13px;
 font-weight: 600;
 backdrop-filter: blur(8px);
 display: flex;
 align-items: center;
 gap: 6px;
}

/* ASI CREDENTIAL STRIP */
.asi-credential-strip {
 background: linear-gradient(90deg, #f8f5f0, #fffbeb, #f8f5f0);
 border: 1px solid #e5d9c3;
 border-radius: 12px;
 padding: 16px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.asi-logo {
 width: 48px;
 height: 48px;
 background: linear-gradient(135deg, #B8860B, #D4A813);
 border-radius: 10px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
 color: white;
 flex-shrink: 0;
 box-shadow: 0 4px 12px rgba(184, 134, 11, 0.25);
}

.asi-text {
 flex: 1;
}

.asi-text .label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1px;
 color: #92400e;
 font-weight: 700;
}

.asi-text .title {
 font-size: 15px;
 color: #78350f;
 font-weight: 600;
 margin-top: 2px;
}

/* TABLE OF CONTENTS */
.toc-box {
 background: transparent;
 border: none;
 border-radius: 0;
 padding: 0;
 margin-bottom: 40px;
}

.toc-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #6b7280;
 font-weight: 700;
 margin-bottom: 16px;
 display: block;
}

.toc-list {
 list-style: none;
 display: grid;
 grid-template-columns: repeat(auto-fit, minmax(200px, 1fr));
 gap: 8px;
}

.toc-list li a {
 display: flex;
 align-items: center;
 gap: 10px;
 padding: 10px 14px;
 background: #f9fafb;
 border: none;
 border-radius: 8px;
 text-decoration: none;
 color: #374151;
 font-size: 14px;
 font-weight: 500;
 transition: all 0.2s;
}

.toc-list li a:hover {
 background: #fdf2f4;
 color: #722F37;
 transform: translateX(4px);
}

.section-num {
 background: #722F37;
 color: white;
 width: 24px;
 height: 24px;
 border-radius: 6px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 11px;
 font-weight: 700;
 flex-shrink: 0;
}

/* WELCOME BOX */
.welcome-box {
 background: linear-gradient(135deg, #fefbf3 0%, #f8f5f0 100%);
 padding: 28px;
 margin-bottom: 40px;
 border-radius: 16px;
 border-left: 5px solid #B8860B;
 box-shadow: 0 4px 12px rgba(0, 0, 0, 0.04);
}

.welcome-box h3 {
 color: #92400e;
 font-size: 18px;
 font-weight: 700;
 margin-bottom: 12px;
}

/* OBJECTIVES BOX */
.objectives-box {
 background: linear-gradient(135deg, #faf5ff 0%, #f3e8ff 100%);
 border-radius: 16px;
 padding: 28px;
 margin-bottom: 40px;
 border: 1px solid #e9d5ff;
}

.box-label {
 font-weight: 700;
 color: #722F37;
 text-transform: uppercase;
 letter-spacing: 1px;
 font-size: 12px;
 margin-bottom: 16px;
 display: block;
}

.objectives-box li {
 padding: 10px 0 10px 32px;
 position: relative;
 font-size: 16px;
 color: #4c1d95;
 list-style: none;
}

.objectives-box li::before {
 content: 'âœ“';
 position: absolute;
 left: 0;
 color: #722F37;
 font-weight: 700;
}

/* TYPOGRAPHY */
h2 {
 color: #722F37;
 font-size: 28px;
 margin: 56px 0 24px 0;
 font-weight: 800;
 position: relative;
 padding-bottom: 16px;
}

h2::after {
 content: '';
 position: absolute;
 bottom: 0;
 left: 0;
 width: 60px;
 height: 4px;
 background: linear-gradient(90deg, #B8860B, #D4A813);
 border-radius: 2px;
}

h3 {
 color: #722F37;
 font-size: 22px;
 margin: 36px 0 16px 0;
 font-weight: 700;
}

.highlight {
 background: linear-gradient(120deg, #fef3c7 0%, #fef3c7 100%);
 padding: 1px 6px;
 border-radius: 4px;
 font-weight: 600;
 color: inherit;
}

/* CASE STUDY */
.case-study {
 background: white;
 border-radius: 20px;
 margin: 40px 0;
 border: 1px solid #e5e7eb;
 box-shadow: 0 8px 30px rgba(0, 0, 0, 0.06);
 overflow: hidden;
 border-left: 5px solid #722F37;
}

.case-study-header {
 background: linear-gradient(90deg, #722F37, #722F37);
 padding: 20px 28px;
 display: flex;
 align-items: center;
 gap: 16px;
}

.case-study-icon {
 width: 48px;
 height: 48px;
 background: rgba(255, 255, 255, 0.2);
 border-radius: 12px;
 display: flex;
 align-items: center;
 justify-content: center;
 font-size: 24px;
}

.case-study-header .title {
 color: white;
 font-weight: 700;
 font-size: 16px;
 margin: 0;
}

.case-study-content {
 padding: 28px;
}

/* COACH TIP BOX */
.coach-tip {
 background: linear-gradient(135deg, #fefce8 0%, #fef9c3 100%);
 border: 1px solid #fde047;
 border-radius: 16px;
 padding: 24px 28px;
 margin: 32px 0;
 position: relative;
}

.coach-tip .tip-label {
 font-size: 11px;
 text-transform: uppercase;
 letter-spacing: 1.5px;
 color: #a16207;
 font-weight: 700;
 margin-bottom: 8px;
 display: block;
}

/* DATA TABLE */
.data-table {
 width: 100%;
 border-collapse: collapse;
 margin: 25px 0;
 font-size: 15px;
 border-radius: 12px;
 overflow: hidden;
 box-shadow: 0 4px 12px rgba(0,0,0,0.05);
}
.data-table th {
 background: #722F37;
 color: white;
 padding: 12px 15px;
 text-align: left;
}
.data-table td {
 padding: 12px 15px;
 border-bottom: 1px solid #e5e7eb;
}
.data-table tr:nth-child(even) {
 background: #f9fafb;
}

/* CHECK YOUR UNDERSTANDING */
.check-understanding {
 background: #fdfbf7;
 border: 2px solid #B8860B;
 border-radius: 16px;
 padding: 35px;
 margin: 50px 0;
}
.check-understanding .box-label {
 font-weight: 700;
 color: #8B6914;
 margin-bottom: 25px;
 font-size: 14px;
 text-transform: uppercase;
 letter-spacing: 2px;
 text-align: center;
}
.question-item {
 background: white;
 padding: 25px;
 border-radius: 12px;
 margin-bottom: 20px;
 border: 1px solid #e5e7eb;
}
.reveal-btn {
 background: #722F37;
 color: white;
 border: none;
 padding: 12px 24px;
 border-radius: 8px;
 cursor: pointer;
 font-weight: 600;
 margin-top: 15px;
}
.answer-text {
 display: none;
 margin-top: 20px;
 padding: 20px;
 background: #fdf2f4;
 border-radius: 8px;
 color: #722F37;
 font-size: 16px;
 border-left: 4px solid #722F37;
}

/* TAKEAWAYS BOX */
.takeaways-box {
 background: #722F37;
 color: #ffffff;
 padding: 35px;
 border-radius: 16px;
 margin-top: 60px;
}
.takeaways-box .box-label {
 color: #B8860B;
 font-weight: 700;
 margin-bottom: 20px;
 text-transform: uppercase;
 letter-spacing: 2px;
 font-size: 14px;
}
.takeaways-box ul {
 margin: 0;
 padding-left: 20px;
}
.takeaways-box li {
 margin-bottom: 12px;
 color: #ffffff;
 list-style: disc;
}

/* REFERENCES BOX */
.references-box {
 background: linear-gradient(135deg, #f8fafc 0%, #f1f5f9 100%);
 border: 1px solid #e2e8f0;
 border-radius: 16px;
 padding: 28px 32px;
 margin-top: 48px;
}
.references-box li {
 margin-bottom: 10px;
 font-size: 14px;
 color: #475569;
}

/* MODULE CONNECTION */
.module-connection {
 background: linear-gradient(135deg, #f0f9ff 0%, #e0f2fe 100%);
 border: 1px solid #7dd3fc;
 border-radius: 16px;
 padding: 20px 24px;
 margin-bottom: 32px;
 display: flex;
 align-items: center;
 gap: 16px;
}
.connection-icon {
 font-size: 24px;
}

 </style>
</head>
<body>

<div class="lesson-wrapper">
 <!-- Module Header Card -->
 <div class="module-header-card">
 <span class="module-label">Module 19: L2 Research & Evidence</span>
 <h1 class="lesson-title">The Legacy of the Women's Health Initiative (WHI)</h1>
 <div class="lesson-meta">
 <span class="meta-badge">Lesson 1 of 8</span>
 <span class="meta-badge">15 min read</span>
 <span class="meta-badge">Evidence-Based Practice</span>
 </div>
 </div>

 <!-- ASI Credential Strip -->
 <div class="asi-credential-strip">
 <div class="asi-logo">ASI</div>
 <div class="asi-text">
 <div class="label">Verified Academic Standard</div>
 <div class="title">AccrediPro Standards Instituteâ„¢ Certified Content</div>
 </div>
 </div>

 <!-- Table of Contents -->
 <nav class="toc-box">
 <p class="box-label">Lesson Navigation</p>
 <ul class="toc-list">
 <li><a href="#the-day-the-world-stopped"><span class="section-num">01</span>The 2002 Shockwave</a></li>
 <li><a href="#methodological-flaws"><span class="section-num">02</span>Unmasking the Flaws</a></li>
 <li><a href="#synthetic-vs-bioidentical"><span class="section-num">03</span>The Progestogen Problem</a></li>
 <li><a href="#the-20-year-reckoning"><span class="section-num">04</span>The 20-Year Reckoning</a></li>
 <li><a href="#window-of-opportunity"><span class="section-num">05</span>The Window of Opportunity</a></li>
 <li><a href="#applying-phase"><span class="section-num">06</span>The PROFILE Application</a></li>
 </ul>
 </nav>

 <!-- Module Connection -->
 <div class="module-connection">
 <div class="connection-icon">ðŸ”—</div>
 <div class="connection-text">
 <p>This lesson serves as the bedrock for <strong>Level 2: Research & Evidence</strong>. To master the <strong>P.H.A.S.E. Frameworkâ„¢</strong>, you must understand the historical trauma surrounding Hormone Replacement Therapy (HRT) to effectively guide your clients through modern evidence.</p>
 </div>
 </div>

 <!-- Welcome Box -->
 <div class="welcome-box">
 <h3>Welcome to the Research Deep Dive</h3>
 <p>In the world of menopause care, there is "Before 2002" and "After 2002." The Women's Health Initiative (WHI) remains the most influentialâ€”and arguably the most misunderstoodâ€”clinical trial in womenâ€™s health history. As a specialist, your ability to dismantle the myths born from this study is what separates a coach from a <span class="highlight">credible practitioner</span>. Today, we look past the headlines to the actual data.</p>
 </div>

 <!-- Learning Objectives -->
 <div class="objectives-box">
 <p class="box-label">Learning Objectives</p>
 <ul>
 <li>Analyze the global impact of the 2002 WHI findings on HRT prescribing habits.</li>
 <li>Identify the critical methodological flaws in the original participant selection.</li>
 <li>Distinguish the risk profiles between synthetic progestins and micronized progesterone.</li>
 <li>Interpret the 20-year follow-up data (2022-2024) regarding age-stratified mortality.</li>
 <li>Apply the 'Profile' phase of the PHASE Frameworkâ„¢ to historical data for client education.</li>
 </ul>
 </div>

 <!-- Case Study -->
 <div class="case-study">
 <div class="case-study-header">
 <div class="case-study-icon">ðŸ‘¤</div>
 <div>
 <p class="title">Case Study: The Fear Legacy</p>
 <p class="subtitle">Sarah, 54, Former Registered Nurse</p>
 </div>
 </div>
 <div class="case-study-content">
 <p><strong>Presenting Situation:</strong> Sarah entered surgical menopause at age 45. Despite debilitating hot flashes, brain fog, and bone density loss, she refused HRT. "I remember the day the WHI news broke," she told her coach. "As a nurse, I was told HRT causes breast cancer and strokes. I've suffered for 9 years because I was terrified of the medicine."</p>
 <p><strong>Intervention:</strong> Using the data in this lesson, her specialist showed her the <span class="highlight">age-stratified risk</span> (that the risks applied to women in their 60s and 70s, not her) and the difference between the synthetic progestin used in the study and modern micronized progesterone.</p>
 <p><strong>Outcome:</strong> Sarah felt empowered to seek a prescription for bioidentical HRT. Within 3 months, her cognitive function returned, and her DEXA scan stabilized.</p>
 </div>
 </div>

 <h2 id="the-day-the-world-stopped">The 2002 Shockwave: July 9th</h2>
 <p>On July 9, 2002, the National Institutes of Health (NIH) abruptly halted the estrogen-plus-progestin arm of the Womenâ€™s Health Initiative. The headlines were catastrophic: <strong>"Hormone Therapy Increases Risk of Breast Cancer and Heart Disease."</strong></p>
 
 <p>Within weeks, millions of women threw their prescriptions in the trash. Prescribing rates plummeted by over 50% in the US alone. However, the <span class="highlight">media reporting</span> failed to mention that the absolute risk increase was tinyâ€”only 8 additional cases of breast cancer per 10,000 women per year.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: The Income of Authority</span>
 <p>Practitioners who can explain "Absolute vs. Relative Risk" are highly sought after. Women in their 40s and 50s are desperate for someone to translate "scary headlines" into "personal safety." Specialists in our network often charge <strong>$300+ for an Evidence Review session</strong> because this clarity is priceless to a suffering client.</p>
 </div>

 <h2 id="methodological-flaws">Unmasking the Flaws: The Age Bias Trap</h2>
 <p>The WHI was designed to see if HRT could <em>prevent</em> heart disease in older women, not to see if it was safe for women in the menopause transition. This distinction changed everything.</p>

 <p>Consider the data on the participants:</p>
 <table class="data-table">
 <thead>
 <tr>
 <th>Metric</th>
 <th>WHI Participant Average</th>
 <th>Target Menopause Client</th>
 </tr>
 </thead>
 <tbody>
 <tr>
 <td>Average Age</td>
 <td>63.3 Years Old</td>
 <td>45 - 55 Years Old</td>
 </tr>
 <tr>
 <td>Time Since Menopause</td>
 <td>12+ Years</td>
 <td>0 - 5 Years</td>
 </tr>
 <tr>
 <td>Pre-existing Health</td>
 <td>35% Obese, 36% Hypertensive</td>
 <td>Varied (Often healthy transitioners)</td>
 </tr>
 </tbody>
 </table>

 <p>The study attempted to start hormones in women who were often <strong>over a decade past their final period</strong>. By this time, many already had subclinical atherosclerosis. Introducing oral estrogen to an older, inflamed cardiovascular system is vastly different than supporting a 50-year-old with healthy arteries.</p>

 <h2 id="synthetic-vs-bioidentical">Synthetic vs. Bioidentical: The Progestogen Problem</h2>
 <p>One of the most critical oversights of the WHI was the use of <strong>Medroxyprogesterone Acetate (MPA)</strong>, a synthetic progestin. We now know that the "breast cancer risk" seen in the study was almost entirely attributable to the MPA, not the estrogen.</p>
 
 <ul>
 <li><strong>WHI Arm 1 (Estrogen + MPA):</strong> Increased breast cancer risk after 5 years.</li>
 <li><strong>WHI Arm 2 (Estrogen Only - for women with hysterectomy):</strong> Actually showed a <span class="highlight">reduction</span> in breast cancer risk and mortality.</li>
 </ul>

 <p>Modern consensus (supported by the French E3N study) shows that <strong>micronized progesterone</strong> (bioidentical) does not carry the same breast cancer risk profile as the synthetic MPA used in the 2002 trial.</p>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: Language Matters</span>
 <p>When speaking with clients, always distinguish between "Progestogens" (the umbrella term), "Progestins" (synthetic), and "Progesterone" (bioidentical). Using the correct terminology builds your <span class="highlight">professional legitimacy</span> immediately.</p>
 </div>

 <h2 id="the-20-year-reckoning">The 20-Year Reckoning (2022-2024)</h2>
 <p>In 2024, JAMA published a 20-year follow-up of the WHI participants. The findings were a complete reversal of the 2002 "fear" narrative for younger women.</p>
 
 <p>A meta-analysis of the data (n=16,000+) showed that for women aged 50-59, the <strong>Hazard Ratio for all-cause mortality was 0.69</strong>. This means that women who started HRT in their 50s had a <strong>31% lower risk of dying</strong> from any cause over the next two decades compared to those on placebo.</p>

 <h2 id="window-of-opportunity">The Window of Opportunity Hypothesis</h2>
 <p>The "Window of Opportunity" is the cornerstone of modern menopause research. It suggests that HRT is neuroprotective and cardioprotective when started <strong>within 10 years of menopause</strong> or before age 60.</p>

 <p>Starting HRT during this window:</p>
 <ul>
 <li>Reduces the accumulation of amyloid-beta in the brain.</li>
 <li>Slows the progression of carotid intima-media thickness (CIMT).</li>
 <li>Preserves bone mineral density before the rapid "drop-off" phase.</li>
 </ul>

 <div class="coach-tip">
 <span class="tip-label">Coach Tip: The PHASE Frameworkâ„¢ Connection</span>
 <p>This is why the <strong>PROFILE</strong> pillar is first. We must identify where a woman is in her timeline. If she is 68 and 20 years post-menopause, her risk profile is different than a 51-year-old in perimenopause. You are not just a coach; you are a <strong>Timeline Strategist</strong>.</p>
 </div>

 <h2 id="applying-phase">Applying the PROFILE Pillar to WHI Data</h2>
 <p>When you use the PHASE Frameworkâ„¢, you are looking for the client's unique <strong>Profile</strong>. The WHI failed because it treated all women as one "Profile."</p>

 <p><strong>To improve client communication, use these three "Evidence Pillars":</strong></p>
 <ol>
 <li><strong>Age Stratification:</strong> Risk is age-dependent. What is risky at 70 is often protective at 50.</li>
 <li><strong>Route of Administration:</strong> The WHI used oral estrogen (which increases clotting factors). Modern transdermal (patches/gels) bypasses the liver and carries almost zero clot risk.</li>
 <li><strong>Type of Progestogen:</strong> Progesterone is the "friendly" hormone; Progestins were the "culprit" in the WHI.</li>
 </ol>

 <!-- Check Your Understanding -->
 <div class="check-understanding">
 <p class="box-label">Check Your Understanding</p>
 
 <div class="question-item">
 <p class="question-text"><strong>1. What was the average age of the participants in the 2002 WHI study?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans1')">Reveal Answer</button>
 <div id="ans1" class="answer-text">The average age was 63.3 years old, which is over a decade past the average age of menopause (51). This created a significant "age bias" in the results.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>2. Which specific hormone was linked to the increased breast cancer risk in the WHI?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans2')">Reveal Answer</button>
 <div id="ans2" class="answer-text">Medroxyprogesterone Acetate (MPA), a synthetic progestin. Women in the estrogen-only arm actually saw a <em>reduction</em> in breast cancer risk.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>3. According to the 2024 JAMA follow-up, what was the mortality benefit for women starting HRT in their 50s?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans3')">Reveal Answer</button>
 <div id="ans3" class="answer-text">There was a 31% reduction in all-cause mortality (Hazard Ratio 0.69) for women aged 50-59 compared to the placebo group.</div>
 </div>

 <div class="question-item">
 <p class="question-text"><strong>4. What is the "Window of Opportunity" for starting HRT?</strong></p>
 <button class="reveal-btn" onclick="toggleAnswer('ans4')">Reveal Answer</button>
 <div id="ans4" class="answer-text">Starting HRT within 10 years of the final menstrual period or before the age of 60 to maximize cardiovascular and neurological benefits.</div>
 </div>
 </div>

 <!-- Takeaways Box -->
 <div class="takeaways-box">
 <p class="box-label">Key Takeaways</p>
 <ul>
 <li>The 2002 WHI study caused a "generation of lost health" for women who were scared away from beneficial therapy.</li>
 <li>Methodological flaws, specifically the high average age of participants, skewed the cardiovascular risk data.</li>
 <li>Synthetic progestins (MPA) carry risks that bioidentical micronized progesterone does not appear to share.</li>
 <li>Modern evidence (2022-2024) confirms that for the symptomatic woman in her 50s, the benefits of HRT typically far outweigh the risks.</li>
 <li>As a specialist, your role is to use the <strong>PROFILE</strong> pillar to help clients understand where they sit on the risk-benefit spectrum.</li>
 </ul>
 </div>

 <!-- References Box -->
 <div class="references-box">
 <p class="box-label">References & Further Reading</p>
 <ul>
 <li>Manson, J. E., et al. (2024). "The Womenâ€™s Health Initiative: 20-Year Follow-up and Modern Clinical Implications." <em>Journal of the American Medical Association (JAMA)</em>.</li>
 <li>Hodis, H. N., et al. (2016). "Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol." <em>New England Journal of Medicine</em>.</li>
 <li>Lâ€™Hermite, M. (2017). "The 'Window of Opportunity' Hypothesis: Where do we stand 15 years after the WHI?" <em>Maturitas</em>.</li>
 <li>Fournier, A., et al. (2008). "Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study." <em>Breast Cancer Research and Treatment</em>.</li>
 <li>Rossouw, J. E., et al. (2002). "Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial." <em>JAMA</em>.</li>
 <li>NAMS (2022). "The 2022 Hormone Therapy Position Statement of The North American Menopause Society." <em>Menopause Journal</em>.</li>
 </ul>
 </div>
</div>

<script>
function toggleAnswer(id) {
 const el = document.getElementById(id);
 if (el.style.display === 'block') {
 el.style.display = 'none';
 } else {
 el.style.display = 'block';
 }
}
</script>

</body>
</html>